Table of Contents Author Guidelines Submit a Manuscript
Neural Plasticity
Volume 2015, Article ID 708306, 12 pages
http://dx.doi.org/10.1155/2015/708306
Review Article

Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body Inflammation in Bipolar Disorder?

1MiNDS Neuroscience Graduate Program, McMaster University, Hamilton, ON, Canada L8S 4L8
2Mood Disorders Program and Women’s Health Concerns Clinic, St. Joseph’s Healthcare, Hamilton, ON, Canada L8P 3B6
3Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada L8S 4L8

Received 15 October 2014; Revised 2 February 2015; Accepted 5 February 2015

Academic Editor: Preston E. Garraghty

Copyright © 2015 Jay P. Patel and Benicio N. Frey. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Ribatti, B. Nico, E. Crivellato, and M. Artico, “Development of the blood-brain barrier: a historical point of view,” Anatomical Record—Part B New Anatomist, vol. 289, no. 1, pp. 3–8, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. A. D. Wong, M. Ye, A. F. Levy, J. D. Rothstein, D. E. Bergles, and P. C. Searson, “The blood-brain barrier: an engineering perspective,” Frontiers in Neuroengineering, vol. 6, article 7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. M. W. Bradbury, “The blood-brain barrier,” Experimental Physiology, vol. 78, no. 4, pp. 453–472, 1993. View at Publisher · View at Google Scholar
  4. B. V. Zlokovic, “The blood-brain barrier in health and chronic neurodegenerative disorders,” Neuron, vol. 57, no. 2, pp. 178–201, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Nitta, M. Hata, S. Gotoh et al., “Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice,” The Journal of Cell Biology, vol. 161, no. 3, pp. 653–660, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. S.-W. Lee, W. J. Kim, Y. K. Choi et al., “SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier,” Nature Medicine, vol. 9, no. 7, pp. 900–906, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Engelhardt and L. Sorokin, “The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction,” Seminars in Immunopathology, vol. 31, no. 4, pp. 497–511, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. C. E. Johanson, E. G. Stopa, and P. N. McMillan, “The blood-cerebrospinal fluid barrier: structure and functional significance,” Methods in Molecular Biology, vol. 686, pp. 101–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Laterra, R. Keep, L. A. Betz, and G. W. Goldstein, Blood—Cerebrospinal Fluid Barrier, Lippincott-Raven, 1999.
  10. C. Nilsson, M. Lindvall-Axelsson, and C. Owman, “Neuroendocrine regulatory mechanisms in the choroid plexus-cerebrospinal fluid system,” Brain Research Reviews, vol. 17, no. 2, pp. 109–138, 1992. View at Publisher · View at Google Scholar · View at Scopus
  11. A. V. Lorenzo, “Factors governing the composition of the cerebrospinal fluid,” Experimental Eye Research, vol. 25, supplement, pp. 205–228, 1977. View at Publisher · View at Google Scholar · View at Scopus
  12. W. M. Pardridge, “Molecular biology of the blood-brain barrier,” Molecular Biotechnology, vol. 30, no. 1, pp. 57–69, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. W. M. Pardridge, J. Eisenberg, and J. Yang, “Human blood-brain barrier transferrin receptor,” Metabolism, vol. 36, no. 9, pp. 892–895, 1987. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Shawahna, Y. Uchida, X. Declèves et al., “Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels,” Molecular Pharmaceutics, vol. 8, no. 4, pp. 1332–1341, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Uchida, S. Ohtsuki, Y. Katsukura et al., “Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors,” Journal of Neurochemistry, vol. 117, no. 2, pp. 333–345, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Gould and C. G. Gross, “Neurogenesis in adult mammals: some progress and problems,” Journal of Neuroscience, vol. 22, no. 3, pp. 619–623, 2002. View at Google Scholar · View at Scopus
  17. I. A. Simpson, A. Carruthers, and S. J. Vannucci, “Supply and demand in cerebral energy metabolism: the role of nutrient transporters,” Journal of Cerebral Blood Flow and Metabolism, vol. 27, no. 11, pp. 1766–1791, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. R. A. Hawkins, R. L. O'Kane, I. A. Simpson, and J. R. Viña, “Structure of the blood-brain barrier and its role in the transport of amino acids,” Journal of Nutrition, vol. 136, no. 1, supplement, pp. 218S–226S, 2006. View at Google Scholar · View at Scopus
  19. B. V. Zlokovic, M. N. Lipovac, D. J. Begley, H. Davson, and L. Rakić, “Transport of leucine-enkephalin across the blood-brain barrier in the perfused guinea pig brain,” Journal of Neurochemistry, vol. 49, no. 1, pp. 310–315, 1987. View at Publisher · View at Google Scholar · View at Scopus
  20. B. V. Zlokovic, S. Hyman, J. G. McComb, M. N. Lipovac, G. Tang, and H. Davson, “Kinetics of arginine-vasopressin uptake at the blood-brain barrier,” Biochimica et Biophysica Acta, vol. 1025, no. 2, pp. 191–198, 1990. View at Publisher · View at Google Scholar · View at Scopus
  21. W. A. Banks, “The CNS as a target for peptides and peptide-based drugs,” Expert Opinion on Drug Delivery, vol. 3, no. 6, pp. 707–712, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. B. V. Zlokovic, S. Jovanovic, W. Miao, S. Samara, S. Verma, and C. L. Farrell, “Differential regulation of leptin transport by the choroid plexus and blood-brain barrier and high affinity transport systems for entry into hypothalamus and across the blood-cerebrospinal fluid barrier,” Endocrinology, vol. 141, no. 4, pp. 1434–1441, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Meresse, C. Delbart, J.-C. Fruchart, and R. Cecchelli, “Low-density lipoprotein receptor on endothelium of brain capillaries,” Journal of Neurochemistry, vol. 53, no. 2, pp. 340–345, 1989. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Deane, A. Sagare, K. Hamm et al., “IgG-assisted age-dependent clearance of Alzheimer's amyloid β peptide by the blood-brain barrier neonatal Fc receptor,” Journal of Neuroscience, vol. 25, no. 50, pp. 11495–11503, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Grotta, M. Moskowitz, T. Jacobs et al., Report of the Stroke Progress Review Group, National Institute of Neurological Disorders and Stroke, 2002, http://www.ninds.nih.gov/about_ninds/groups/stroke_prg/strokeprgreport-4-23-02.pdf.
  26. N. J. Abbott, L. Rönnbäck, and E. Hansson, “Astrocyte-endothelial interactions at the blood-brain barrier,” Nature Reviews Neuroscience, vol. 7, no. 1, pp. 41–53, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. E. A. Neuwelt, B. Bauer, C. Fahlke et al., “Engaging neuroscience to advance translational research in brain barrier biology,” Nature Reviews Neuroscience, vol. 12, no. 3, pp. 169–182, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. N. J. Abbott and A. Friedman, “Overview and introduction: the blood-brain barrier in health and disease,” Epilepsia, vol. 53, supplement 6, pp. 1–6, 2012. View at Google Scholar · View at Scopus
  29. S. Najjar, D. M. Pearlman, S. Hirsch et al., “Brain biopsy findings link major depressive disorder to neuroinflammation, oxidative stress, and neurovascular dysfunction: a case report,” Biological Psychiatry, vol. 75, no. 12, pp. e23–e26, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Simard, G. Arcuino, T. Takano, Q. S. Liu, and M. Nedergaard, “Signaling at the gliovascular interface,” The Journal of Neuroscience, vol. 23, no. 27, pp. 9254–9262, 2003. View at Google Scholar · View at Scopus
  31. G. J. del Zoppo, “The neurovascular unit, matrix proteases, and innate inflammation,” Annals of the New York Academy of Sciences, vol. 1207, pp. 46–49, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. C. R. Figley and P. W. Stroman, “The role(s) of astrocytes and astrocyte activity in neurometabolism, neurovascular coupling, and the production of functional neuroimaging signals,” European Journal of Neuroscience, vol. 33, no. 4, pp. 577–588, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. G. R. J. Gordon, S. J. Mulligan, and B. A. MacVicar, “Astrocyte control of the cerebrovasculature,” Glia, vol. 55, no. 12, pp. 1214–1221, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. J. A. Filosa, “Vascular tone and neurovascular coupling: considerations toward an improved in vitro model,” Frontiers in Neuroenergetics, vol. 2, article 16, 2010. View at Publisher · View at Google Scholar
  35. R. Kraemer and B. L. Hempstead, “Neurotrophins: novel mediators of angiogenesis,” Frontiers in Bioscience, vol. 8, pp. s1181–s1186, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. N. L. Ward and J. C. Lamanna, “The neurovascular unit and its growth factors: coordinated response in the vascular and nervous systems,” Neurological Research, vol. 26, no. 8, pp. 870–883, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. V. Muoio, P. B. Persson, and M. M. Sendeski, “The neurovascular unit—concept review,” Acta Physiologica, vol. 210, no. 4, pp. 790–798, 2014. View at Publisher · View at Google Scholar
  38. S. Soker, H.-Q. Miao, M. Nomi, S. Takashima, and M. Klagsbrun, “VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding,” Journal of Cellular Biochemistry, vol. 85, no. 2, pp. 357–368, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Sanchez, D. Tripathy, J. Luo, X. Yin, J. Martinez, and P. Grammas, “Neurovascular unit and the effects of dosage in VEGF toxicity: role for oxidative stress and thrombin,” Journal of Alzheimer's Disease, vol. 34, no. 1, pp. 281–291, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. R. D. Fields and B. Stevens-Graham, “Neuroscience: new insights into neuron-glia communication,” Science, vol. 298, no. 5593, pp. 556–562, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Kowiański, G. Lietzau, A. Steliga, M. WaŚkow, and J. MoryŚ, “The astrocytic contribution to neurovascular coupling—still more questions than answers?” Neuroscience Research, vol. 75, no. 3, pp. 171–183, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. K. L. Lavoie, R. Pelletier, A. Arsenault, J. Dupuis, and S. L. Bacon, “Association between clinical depression and endothelial function measured by forearm hyperemic reactivity,” Psychosomatic Medicine, vol. 72, no. 1, pp. 20–26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Politi, N. Brondino, and E. Emanuele, “Increased proapoptotic serum activity in patients with chronic mood disorders,” Archives of Medical Research, vol. 39, no. 2, pp. 242–245, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. V. Valkanova and K. P. Ebmeier, “Vascular risk factors and depression in later life: a systematic review and meta-analysis,” Biological Psychiatry, vol. 73, no. 5, pp. 406–413, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. B. V. Zlokovic, “Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders,” Nature Reviews Neuroscience, vol. 12, no. 12, pp. X723–738, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Takeda, N. Sato, and R. Morishita, “Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy,” Frontiers in Aging Neuroscience, vol. 6, article 171, 2014. View at Publisher · View at Google Scholar
  47. E. C. Phillips, C. L. Croft, K. Kurbatskaya et al., “Astrocytes and neuroinflammation in Alzheimer’s disease,” Biochemical Society Transactions, vol. 42, no. 5, pp. 1321–1325, 2014. View at Publisher · View at Google Scholar
  48. R. Deane, S. D. Yan, R. K. Submamaryan et al., “RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain,” Nature Medicine, vol. 9, no. 7, pp. 907–913, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. J. E. Donahue, S. L. Flaherty, C. E. Johanson et al., “RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease,” Acta Neuropathologica, vol. 112, no. 4, pp. 405–415, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Deane, Z. Wu, A. Sagare et al., “LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms,” Neuron, vol. 43, no. 3, pp. 333–344, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. R. D. Bell, R. Deane, N. Chow et al., “SRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells,” Nature Cell Biology, vol. 11, no. 2, pp. 143–153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. M. A. Erickson, P. E. Hartvigson, Y. Morofuji, J. B. Owen, D. A. Butterfield, and W. A. Banks, “Lipopolysaccharide impairs amyloid beta efflux from brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood-brain barrier,” Journal of Neuroinflammation, vol. 9, article 150, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Shibata, S. Yamada, S. Ram Kumar et al., “Clearance of Alzheimer's amyloid-β1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier,” Journal of Clinical Investigation, vol. 106, no. 12, pp. 1489–1499, 2000. View at Publisher · View at Google Scholar · View at Scopus
  54. R. D. Bell, A. P. Sagare, A. E. Friedman et al., “Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system,” Journal of Cerebral Blood Flow and Metabolism, vol. 27, no. 5, pp. 909–918, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. A. H. Abuznait and A. Kaddoumi, “Role of ABC transporters in the pathogenesis of Alzheimers disease,” ACS Chemical Neuroscience, vol. 3, no. 11, pp. 820–831, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Kuhnke, G. Jedlitschky, M. Grube et al., “MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-β peptides—implications for the mechanisms of Aβ clearance at the blood-brain barrier,” Brain Pathology, vol. 17, no. 4, pp. 347–353, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. J. R. Cirrito, R. Deane, A. M. Fagan et al., “P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model,” Journal of Clinical Investigation, vol. 115, no. 11, pp. 3285–3290, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Lassmann, “Multiple sclerosis: is there neurodegeneration independent from inflammation?” Journal of the Neurological Sciences, vol. 259, no. 1-2, pp. 3–6, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. B. D. Trapp and K.-A. Nave, “Multiple sclerosis: an immune or neurodegenerative disorder?” Annual Review of Neuroscience, vol. 31, pp. 247–269, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. R. M. Ransohoff, P. Kivisäkk, and G. Kidd, “Three or more routes for leukocyte migration into the central nervous system,” Nature Reviews Immunology, vol. 3, no. 7, pp. 569–581, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. B. Engelhardt and R. M. Ransohoff, “The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms,” Trends in Immunology, vol. 26, no. 9, pp. 485–495, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Man, E. E. Ubogu, and R. M. Ransohoff, “Inflammatory cell migration into the central nervous system: a few new twists on an old tale,” Brain Pathology, vol. 17, no. 2, pp. 243–250, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. S. P. Cramer, H. Simonsen, J. L. Frederiksen, E. Rostrup, and H. B. W. Larsson, “Abnormal blood-brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI,” NeuroImage: Clinical, vol. 4, pp. 182–189, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Kraus, K. Voigt, A. M. Schuller et al., “Interferon-β stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro,” Multiple Sclerosis, vol. 14, no. 6, pp. 843–852, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. F. Shimizu, A. Tasaki, Y. Sano et al., “Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier,” PLoS ONE, vol. 9, no. 3, Article ID e92872, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. B. Cauwe, P. E. van den Steen, and G. Opdenakker, “The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases,” Critical Reviews in Biochemistry and Molecular Biology, vol. 42, no. 3, pp. 113–185, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. G. A. Rosenberg, “Matrix metalloproteinases and their multiple roles in neurodegenerative diseases,” The Lancet Neurology, vol. 8, no. 2, pp. 205–216, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. V. W. Yong, C. Power, P. Forsyth, and D. R. Edwards, “Metalloproteinases in biology and pathology of the nervous system,” Nature Reviews Neuroscience, vol. 2, no. 7, pp. 502–511, 2001. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Gardner and A. Ghorpade, “Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system,” Journal of Neuroscience Research, vol. 74, no. 6, pp. 801–806, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. E. Stomrud, M. Björkqvist, S. Janciauskiene, L. Minthon, and O. Hansson, “Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease,” Alzheimer's Research & Therapy, vol. 2, no. 3, article 20, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. G. F. Hamann, Y. Okada, R. Fitridge, G. J. del Zoppo, and J. T. Povlishock, “Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion,” Stroke, vol. 26, no. 11, pp. 2120–2126, 1995. View at Publisher · View at Google Scholar · View at Scopus
  72. J. H. Heo, J. Lucero, T. Abumiya, J. A. Koziol, B. R. Copeland, and G. J. Del Zoppo, “Matrix metalloproteinases increase very early during experimental focal cerebral ischemia,” Journal of Cerebral Blood Flow and Metabolism, vol. 19, no. 6, pp. 624–633, 1999. View at Google Scholar · View at Scopus
  73. Y. Gasche, J.-C. Copin, T. Sugawara, M. Fujimura, and P. H. Chan, “Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia,” Journal of Cerebral Blood Flow and Metabolism, vol. 21, no. 12, pp. 1393–1400, 2001. View at Google Scholar · View at Scopus
  74. K. Gijbels, S. Masure, H. Carton, and G. Opdenakker, “Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders,” Journal of Neuroimmunology, vol. 41, no. 1, pp. 29–34, 1992. View at Publisher · View at Google Scholar · View at Scopus
  75. G. A. Rosenberg, J. E. Dencoff, N. Correa Jr., M. Reiners, and C. C. Ford, “Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury,” Neurology, vol. 46, no. 6, pp. 1626–1632, 1996. View at Publisher · View at Google Scholar · View at Scopus
  76. K. Gijbels, R. E. Galardy, and L. Steinman, “Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases,” The Journal of Clinical Investigation, vol. 94, no. 6, pp. 2177–2182, 1994. View at Publisher · View at Google Scholar · View at Scopus
  77. C. Reitz, F. J. A. van Rooij, H. D. Soares et al., “Matrix metalloproteinase 3 haplotypes and plasma amyloid beta levels: the Rotterdam Study,” Neurobiology of Aging, vol. 31, no. 4, pp. 715–718, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Lorenzl, D. S. Albers, N. Relkin et al., “Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease,” Neurochemistry International, vol. 43, no. 3, pp. 191–196, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. J. R. Backstrom, G. P. Lim, M. J. Cullen, and Z. A. Tökés, “Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40),” Journal of Neuroscience, vol. 16, no. 24, pp. 7910–7919, 1996. View at Google Scholar · View at Scopus
  80. H. Mizoguchi, K. Takuma, E. Fukuzaki et al., “Matrix metalloprotease-9 inhibition improves amyloid β-mediated cognitive impairment and neurotoxicity in mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 331, no. 1, pp. 14–22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. D. G. Kirch, C. A. Kaufmann, N. M. Papadopoulos, B. Martin, and D. R. Weinberger, “Abnormal cerebrospinal fluid protein indices in schizophrenia,” Biological Psychiatry, vol. 20, no. 10, pp. 1039–1046, 1985. View at Publisher · View at Google Scholar · View at Scopus
  82. K. Bauer and J. Kornhuber, “Blood-cerebrospinal fluid barrier in schizophrenic patients,” European Archives of Psychiatry and Neurological Sciences, vol. 236, no. 5, pp. 257–259, 1987. View at Publisher · View at Google Scholar · View at Scopus
  83. E. G. Severance, K. L. Gressitt, A. Alaedini et al., “IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia,” Brain, Behavior, and Immunity, vol. 44, pp. 148–158, 2015. View at Publisher · View at Google Scholar
  84. H. Zetterberg, J. Jakobsson, M. Redsäter et al., “Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment,” Psychiatry Research, vol. 217, no. 3, pp. 143–146, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. K. Bechter, H. Reiber, S. Herzog, D. Fuchs, H. Tumani, and H. G. Maxeiner, “Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction,” Journal of Psychiatric Research, vol. 44, no. 5, pp. 321–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. C. Hammer, B. Stepniak, A. Schneider et al., “Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity,” Molecular Psychiatry, vol. 19, pp. 1143–1149, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. M. J. Titulaer and J. Dalmau, “Antibodies to NMDA receptor, blood-brain barrier disruption and schizophrenia: a theory with unproven links,” Molecular Psychiatry, vol. 19, article 1054, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. E. G. Hughes, X. Peng, A. J. Gleichman et al., “Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis,” The Journal of Neuroscience, vol. 30, no. 17, pp. 5866–5875, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. E. Moscato, X. Peng, T. Parsons, J. Dalmau, and R. Balice-Gordon, “No title,” Journal of Neuroimmunology, vol. 253, no. 145, 2012, Abstrat 408. View at Google Scholar
  90. C. M. Ramsey, A. P. Spiraa, R. Mojtabai, W. W. Eaton, K. Roth, and H. B. Leeb, “Lifetime manic spectrum episodes and all-cause mortality: 26-year follow-up of the NIMH Epidemiologic Catchment Area Study,” Journal of Affective Disorders, vol. 151, no. 1, pp. 337–342, 2013. View at Publisher · View at Google Scholar · View at Scopus
  91. J. G. Fiedorowicz, D. A. Solomon, J. Endicott et al., “Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder,” Psychosomatic Medicine, vol. 71, no. 6, pp. 598–606, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. F. Angst, H. H. Stassen, P. J. Clayton, and J. Angst, “Mortality of patients with mood disorders: follow-up over 34–38 years,” Journal of Affective Disorders, vol. 68, no. 2-3, pp. 167–181, 2002. View at Publisher · View at Google Scholar · View at Scopus
  93. C. Crump, K. Sundquist, M. A. Winkleby, and J. Sundquist, “Comorbidities and mortality in bipolar disorder: a Swedish national cohort study,” JAMA Psychiatry, vol. 70, no. 9, pp. 931–939, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. D. J. Kupfer, “The increasing medical burden in bipolar disorder,” Journal of the American Medical Association, vol. 293, no. 20, pp. 2528–2530, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. U. Hoang, R. Stewart, and M. J. Goldacre, “Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999–2006,” British Medical Journal, vol. 343, no. 7824, Article ID d5422, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Maes, R. Smith, and S. Scharpe, “The monocyte-T-lymphocyte hypothesis of major depression,” Psychoneuroendocrinology, vol. 20, no. 2, pp. 111–116, 1995. View at Publisher · View at Google Scholar · View at Scopus
  97. L. Stertz, P. V. S. Magalhães, and F. Kapczinski, “Is bipolar disorder an inflammatory condition? The relevance of microglial activation,” Current Opinion in Psychiatry, vol. 26, no. 1, pp. 19–26, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. B. C. M. B. Haarman, R. F. Riemersma-van der Lek, J. C. de Groot et al., “Neuroinflammation in bipolar disorder—a [11C]-(R)-PK11195 positron emission tomography study,” Brain, Behavior, and Immunity, vol. 40, pp. 219–225, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. R. C. Padmos, M. H. J. Hillegers, E. M. Knijff et al., “A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes,” Archives of General Psychiatry, vol. 65, no. 4, pp. 395–407, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. Ł. Drzyzga, E. Obuchowicz, A. Marcinowska, and Z. S. Herman, “Cytokines in schizophrenia and the effects of antipsychotic drugs,” Brain, Behavior, and Immunity, vol. 20, no. 6, pp. 532–545, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. B. B. C. M. Haarman, R. F. R.-V. der Lek, H. Burger et al., “Relationship between clinical features and inflammation-related monocyte gene expression in bipolar disorder—towards a better understanding of psychoimmunological interactions,” Bipolar Disorders, vol. 16, no. 2, pp. 137–150, 2014. View at Publisher · View at Google Scholar · View at Scopus
  102. Y. Che, J.-F. Wang, L. Shao, and L. T. Young, “Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness,” Journal of Psychiatry and Neuroscience, vol. 35, no. 5, pp. 296–302, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Y. Tian, J.-F. Wang, Y. B. Bezchlibnyk, and L. T. Young, “Immunoreactivity of 43 kDa growth-associated protein is decreased in post mortem hippocampus of bipolar disorder and schizophrenia,” Neuroscience Letters, vol. 411, no. 2, pp. 123–127, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. N. Kato, K. Nemoto, H. Arino, and K. Fujikawa, “Influence of peripheral inflammation on growth-associated phosphoprotein (GAP-43) expression in dorsal root ganglia and on nerve recovery after crush injury,” Neuroscience Research, vol. 45, no. 3, pp. 297–303, 2003. View at Publisher · View at Google Scholar · View at Scopus
  105. G. Scola, H. K. Kim, L. T. Young, and A. C. Andreazza, “A fresh look at complex i in microarray data: clues to understanding disease-specific mitochondrial alterations in bipolar disorder,” Biological Psychiatry, vol. 73, no. 2, pp. e4–e5, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. A. C. Andreazza, M. Kauer-Sant'Anna, B. N. Frey et al., “Oxidative stress markers in bipolar disorder: a meta-analysis,” Journal of Affective Disorders, vol. 111, no. 2-3, pp. 135–144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. N. C. Brown, A. C. Andreazza, and L. T. Young, “An updated meta-analysis of oxidative stress markers in bipolar disorder,” Psychiatry Research, vol. 218, no. 1-2, pp. 61–68, 2014. View at Publisher · View at Google Scholar · View at Scopus
  108. C. Konradi, S. E. Sillivan, and H. B. Clay, “Mitochondria, oligodendrocytes and inflammation in bipolar disorder: evidence from transcriptome studies points to intriguing parallels with multiple sclerosis,” Neurobiology of Disease, vol. 45, no. 1, pp. 37–47, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. N. Uranova, D. Orlovskaya, O. Vikhreva et al., “Electron microscopy of oligodendroglia in severe mental illness,” Brain Research Bulletin, vol. 55, no. 5, pp. 597–610, 2001. View at Publisher · View at Google Scholar · View at Scopus
  110. D. D. Orlovskaya, V. M. Vostrikov, V. I. Rachmanova, and N. A. Uranova, “Decreased numerical density of oligodendroglial cells in postmortem prefrontal cortex in schizophrenia, bipolar affective disorder and major depression,” Schizophrenia Research, vol. 41, no. 1, pp. 105–106, 2000. View at Publisher · View at Google Scholar
  111. S. Heng, A. W. Song, and K. Sim, “White matter abnormalities in bipolar disorder: insights from diffusion tensor imaging studies,” Journal of Neural Transmission, vol. 117, no. 5, pp. 639–654, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. B. P. Sokolov, “Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies?” The International Journal of Neuropsychopharmacology, vol. 10, no. 4, pp. 547–555, 2007. View at Publisher · View at Google Scholar · View at Scopus
  113. C. Aston, L. Jiang, and B. P. Sokolov, “Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder,” Molecular Psychiatry, vol. 10, no. 3, pp. 309–322, 2005. View at Publisher · View at Google Scholar · View at Scopus
  114. N. R. Herring and C. Konradi, “Myelin, copper, and the cuprizone model of schizophrenia,” Frontiers in Bioscience, vol. 3, no. 1, pp. 23–40, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. B. S. Diniz, R. Machado-Vieira, and O. V. Forlenza, “Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders,” Neuropsychiatric Disease and Treatment, vol. 9, pp. 493–500, 2013. View at Publisher · View at Google Scholar · View at Scopus
  116. G. A. Behr, J. C. F. Moreira, and B. N. Frey, “Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 609421, 13 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  117. I. C. Maurer, P. Schippel, and H.-P. Volz, “Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue,” Bipolar Disorders, vol. 11, no. 5, pp. 515–522, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. P. M. Cummins, “Occludin: one protein, many forms,” Molecular and Cellular Biology, vol. 32, no. 2, pp. 242–250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  119. L. González-Mariscal, R. Tapia, and D. Chamorro, “Crosstalk of tight junction components with signaling pathways,” Biochimica et Biophysica Acta, vol. 1778, no. 3, pp. 729–756, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. J. J. Lochhead, G. Mccaffrey, L. Sanchez-Covarrubias et al., “Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood-brain barrier during inflammatory pain,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 302, no. 3, pp. H582–H593, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. D. L. Murphy, C. Donnelly, and J. Moskowitz, “Inhibition by lithium of prostaglandin E1 and norepinephrine effects on cyclic adenosine monophosphate production in human platelets,” Clinical Pharmacology and Therapeutics, vol. 14, no. 5, pp. 810–814, 1973. View at Google Scholar · View at Scopus
  122. M. Karmazyn, M. S. Manku, and D. F. Horrobin, “Changes of vascular reactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins,” Endocrinology, vol. 102, no. 4, pp. 1230–1236, 1978. View at Publisher · View at Google Scholar · View at Scopus
  123. M. C. Chang, E. Grange, O. Rabin, J. M. Bell, D. D. Allen, and S. I. Rapoport, “Lithium decreases turnover of arachidonate in several brain phospholipids,” Neuroscience Letters, vol. 220, no. 3, pp. 171–174, 1996. View at Publisher · View at Google Scholar
  124. J. S. Rao, H.-J. Lee, S. I. Rapoport, and R. P. Bazinet, “Mode of action of mood stabilizers: is the arachidonic acid cascade a common target?” Molecular Psychiatry, vol. 13, no. 6, pp. 585–596, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. F. Bosetti, J. Rintala, R. Seemann et al., “Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E2 concentration in rat brain,” Molecular Psychiatry, vol. 7, no. 8, pp. 845–850, 2002. View at Publisher · View at Google Scholar · View at Scopus
  126. M. Basselin, H.-W. Kim, M. Chen et al., “Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation,” Journal of Lipid Research, vol. 51, no. 5, pp. 1049–1056, 2010. View at Publisher · View at Google Scholar · View at Scopus
  127. S. Hong, K. Gronert, P. R. Devchand, R.-L. Moussignac, and C. N. Serhan, “Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells: autacoids in anti-inflammation,” The Journal of Biological Chemistry, vol. 278, no. 17, pp. 14677–14687, 2003. View at Publisher · View at Google Scholar · View at Scopus
  128. A. González-Périz, A. Planagumà, K. Gronert et al., “Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA,” The FASEB Journal, vol. 20, no. 14, pp. 2537–2539, 2006. View at Publisher · View at Google Scholar · View at Scopus
  129. W.-F. Tan, X.-Z. Cao, J.-K. Wang, H.-W. Lv, B.-Y. Wu, and H. Ma, “Protective effects of lithium treatment for spatial memory deficits induced by tau hyperphosphorylation in splenectomized rats,” Clinical and Experimental Pharmacology and Physiology, vol. 37, no. 10, pp. 1010–1015, 2010. View at Publisher · View at Google Scholar · View at Scopus
  130. H.-M. Wang, T. Zhang, Q. Li, J.-K. Huang, R.-F. Chen, and X.-J. Sun, “Inhibition of glycogen synthase kinase-3β by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes,” Neurochemistry International, vol. 63, no. 5, pp. 345–353, 2013. View at Publisher · View at Google Scholar · View at Scopus
  131. Y. Wang, W. C. Huang, C. Y. Wang et al., “Inhibiting glycogen synthase kinase-3 reduces endotoxaemic acute renal failure by down-regulating inflammation and renal cell apoptosis,” British Journal of Pharmacology, vol. 157, no. 6, pp. 1004–1013, 2009. View at Publisher · View at Google Scholar · View at Scopus
  132. H. F. Green and Y. M. Nolan, “GSK-3 mediates the release of IL-1β, TNF-α and IL-10 from cortical glia,” Neurochemistry International, vol. 61, no. 5, pp. 666–671, 2012. View at Publisher · View at Google Scholar · View at Scopus
  133. H. Himmerich, S. Bartsch, H. Hamer et al., “Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro,” Journal of Psychiatric Research, vol. 47, no. 11, pp. 1751–1759, 2013. View at Publisher · View at Google Scholar · View at Scopus
  134. T. F. Tay, M. Maheran, S. L. Too, M. S. Hasidah, G. Ismail, and N. Embi, “Glycogen synthase kinase-3β inhibition improved survivability of mice infected with Burkholderia pseudomallei,” Tropical Biomedicine, vol. 29, no. 4, pp. 551–567, 2012. View at Google Scholar · View at Scopus
  135. K. Chen, Y. Wu, M. Zhu et al., “Lithium chloride promotes host resistance against Pseudomonas aeruginosa keratitis,” Molecular Vision, vol. 19, pp. 1502–1514, 2013. View at Google Scholar · View at Scopus
  136. P. Zhang, J. Katz, and S. M. Michalek, “Glycogen synthase kinase-3β (GSK3β) inhibition suppresses the inflammatory response to Francisella infection and protects against tularemia in mice,” Molecular Immunology, vol. 46, no. 4, pp. 677–687, 2009. View at Publisher · View at Google Scholar · View at Scopus
  137. E. Beurel and R. S. Jope, “Glycogen synthase kinase-3 promotes the synergistic action of interferon-γ on lipopolysaccharide-induced IL-6 production in RAW264.7 cells,” Cellular Signalling, vol. 21, no. 6, pp. 978–985, 2009. View at Publisher · View at Google Scholar · View at Scopus
  138. F. Boufidou, C. Nikolaou, B. Alevizos, I. A. Liappas, and G. N. Christodoulou, “Cytokine production in bipolar affective disorder patients under lithium treatment,” Journal of Affective Disorders, vol. 82, no. 2, pp. 309–313, 2004. View at Publisher · View at Google Scholar · View at Scopus
  139. A. L. Rowse, R. Naves, K. S. Cashman et al., “Lithium controls central nervous system autoimmunity through modulation of IFN-γ signaling,” PLoS ONE, vol. 7, no. 12, Article ID e52658, 2012. View at Publisher · View at Google Scholar · View at Scopus
  140. S. Agrawal, S. Gollapudi, S. Gupta, and A. Agrawal, “Dendritic cells from the elderly display an intrinsic defect in the production of IL-10 in response to Lithium Chloride,” Experimental Gerontology, vol. 48, no. 11, pp. 1285–1292, 2013. View at Publisher · View at Google Scholar · View at Scopus
  141. M. H. Rapaport, L. Guylai, and P. Whybrow, “Immune parameters in rapid cycling bipolar patients before and after lithium treatment,” Journal of Psychiatric Research, vol. 33, no. 4, pp. 335–340, 1999. View at Publisher · View at Google Scholar · View at Scopus
  142. E. J. Kucharz, S. J. Sierakowski, and J. S. Goodwin, “Lithium in vitro enhances interleukin-2 production by T cells from patients with systemic lupus erythematosus,” Immunopharmacology and Immunotoxicology, vol. 15, no. 5, pp. 515–523, 1993. View at Publisher · View at Google Scholar · View at Scopus
  143. M. B. Sztein, G. L. Simon, D. M. Parenti et al., “In vitro effects of thymosin and lithium on lymphoproliferative responses of normal donors and HIV seropositive male homosexuals with AIDS-related complex,” Clinical Immunology and Immunopathology, vol. 44, no. 1, pp. 51–62, 1987. View at Publisher · View at Google Scholar · View at Scopus
  144. F. Ballanger, I. Tenaud, C. Volteau, A. Khammari, and B. Dréno, “Anti-inflammatory effects of lithium gluconate on keratinocytes: a possible explanation for efficiency in seborrhoeic dermatitis,” Archives of Dermatological Research, vol. 300, no. 5, pp. 215–223, 2008. View at Publisher · View at Google Scholar · View at Scopus
  145. K. Azim and A. M. Butt, “GSK3β negatively regulates oligodendrocyte differentiation and myelination in vivo,” Glia, vol. 59, no. 4, pp. 540–553, 2011. View at Publisher · View at Google Scholar · View at Scopus
  146. J. K. Rybakowski, A. Remlinger-Molenda, A. Czech-Kucharska, M. Wojcicka, M. Michalak, and J. Losy, “Increased serum matrix metalloproteinase-9 (MMP-9) levels in young patients during bipolar depression,” Journal of Affective Disorders, vol. 146, no. 2, pp. 286–289, 2013. View at Publisher · View at Google Scholar · View at Scopus
  147. B. I. Goldstein, D. E. Kemp, J. K. Soczynska, and R. S. McIntyre, “Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature,” The Journal of Clinical Psychiatry, vol. 70, no. 8, pp. 1078–1090, 2009. View at Publisher · View at Google Scholar · View at Scopus
  148. S. M. Kousik, T. C. Napier, and P. M. Carvey, “The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation,” Frontiers in Pharmacology, vol. 3, article 121, 2012. View at Publisher · View at Google Scholar · View at Scopus
  149. E. O'Shea, A. Urrutia, A. R. Green, and M. I. Colado, “Current preclinical studies on neuroinflammation and changes in blood-brain barrier integrity by MDMA and methamphetamine,” Neuropharmacology, vol. 87, pp. 125–134, 2014. View at Publisher · View at Google Scholar · View at Scopus
  150. R. C. Padmos, G. C. M. Van Baal, R. Vonk et al., “Genetic and environmental influences on pro-inflammatory monocytes in bipolar disorder: a twin study,” Archives of General Psychiatry, vol. 66, no. 9, pp. 957–965, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. A. K. Heye, R. D. Culling, M. D. C. Valdés Hernández, M. J. Thrippleton, and J. M. Wardlaw, “Assessment of blood-brain barrier disruption using dynamic contrast-enhanced MRI. A systematic review,” NeuroImage: Clinical, vol. 6, pp. 262–274, 2014. View at Publisher · View at Google Scholar
  152. N. H. Hendrikse and W. Vaalburg, “Imaging of P glycoprotein function in vivo with PET,” Novartis Foundation Symposium, vol. 243, pp. 137–148, 180–185, 2002. View at Publisher · View at Google Scholar · View at Scopus
  153. E. Candelario-Jalil, Y. Yang, and G. A. Rosenberg, “Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia,” Neuroscience, vol. 158, no. 3, pp. 983–994, 2009. View at Publisher · View at Google Scholar · View at Scopus